Registry of Coronary Disease Outcomes Revascularizing With Drug-Coated Balloons
RECORD-DCB: Registry of Coronary Disease Outcomes Revascularizing With Drug-Coated Balloons
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
3,000 participants
Nov 11, 2025
OBSERVATIONAL
Conditions
Summary
The primary aim of this registry is to systematically collect and analyze real-world data on all patients undergoing PCI with the Protégé paclitaxel-eluting DCB to evaluate procedural outcomes, long-term efficacy, and safety across various clinical indications. This registry aims to assess the clinical effectiveness of DCB therapy across diverse patient populations, including those with stable coronary artery disease (CAD) and acute coronary syndromes (ACS), as well as various lesion subsets, encompassing (but not limited to) in-stent restenosis (ISR), de novo coronary lesions, small vessel disease, bifurcation and calcified lesions, coronary bypass graft lesions, and patients at high risk of bleeding. Additionally, the study aims to identify predictors of success, complications, and optimal treatment strategies to further refine the use of DCBs.
Eligibility
Inclusion Criteria5
- Patients undergoing PCI with the Protégé paclitaxel-eluting DCB
- Age ≥ 18 years
- Presence of a de novo lesion or in-stent restenosis in a native coronary artery or a in a bypass graft and suitable for PCI
- Reference vessel diameter between 2.0 - 4.5 mm
- Patient suitable for dual antiplatelet therapy (DAPT)
Exclusion Criteria2
- Inability to provide informed consent
- Allergy to paclitaxel
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07231835